The Role of Biomarkers in the Management of Muscle-Invasive Bladder Cancer.

Authors

Alec Zhu, Ahmed Eraky, Pierre-Etienne Gabriel, John P Sfakianos

Published in

The Urologic clinics of North America. Volume 53. Issue 4. Pages 601-612. Epub Jul 24, 2026.

Abstract

Muscle-invasive bladder cancer (MIBC) management is evolving beyond traditional clinicopathologic staging to include integration of molecular biomarkers. DNA damage repair gene alterations predict cisplatin sensitivity, while fibroblast growth factor receptor mutations identify candidates for targeted therapy. Transcriptomic subtypes reveal tumor phenotypes with variable treatment responses. Most significantly, circulating tumor DNA (ctDNA) enables dynamic disease monitoring, with postoperative ctDNA detection identifying high-risk patients who benefit from adjuvant immunotherapy while ctDNA-negative patients can safely avoid overtreatment. Despite promising advances, challenges including prospective validation, standardization, and accessibility limit widespread clinical adoption. This article examines current evidence and future directions for biomarker-driven MIBC management.

PMID:
42823051
Bibliographic data and abstract were imported from PubMed on 02 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.